A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Smoldering Multiple Myeloma

Interventions

DRUG: Daratumumab SC: daratumumab + rHuPH20

Sponsor

Janssen Research & Development, LLC